Bìol. Tvarin. 2020; 22 (2): 20–25.
Received 09.04.2020 ▪ Accepted 01.06.2020 ▪ Published online 01.07.2020

Efficiency of danofloxacin in treatment of pig colibacteriosis

T. I. Stetsko

This email address is being protected from spambots. You need JavaScript enabled to view it.

State Scientific Research Control Institute of Veterinary Medicinal Products and Feed Additives,
11 Donetska str., Lviv, 79019, Ukraine

The article presents the study results of the third-generation fluoroquinolone antibiotic danofloxacin efficacy and safeness in the treatment of pig colibacillosis. Susceptibility testing of Escherichia coli field strains isolated from the feces of piglets with acute intestinal infection to danofloxacin was carried out. A high level of E. coli isolates susceptibility to danofloxacin was established: the average diameter of the growth inhibitory zone around the antibiotic disc was 29.1±1.008 mm (n=20) and the average minimum inhibitory concentration (MIC) of danofloxacin for E. coli isolates was 0.28±0.054 µg/ml (n=20). The usage of therapeutic doses of the new danofloxacin-based antimicrobial drug Danoflox 2.5% (solution for injection) caused clinical recovery of piglets with colibacteriosis. During and after antibiotic therapy, no negative reactions or adverse events in animals were observed that indicates about a high level of the drug safeness when administered to pigs at the recommended dosage. The drug safeness and the absence of negative impact on the physiological and functional state of piglets with colibacteriosis were confirmed by the laboratory studies of hematological, immunological and biochemical blood parameters before and after antibiotic therapy. Before treatment in the blood of piglets an increase of hematocrit, erythrocyte and leukocyte count, erythrocyte sedimentation rate, and a high percentage of rod-shaped neutrophils were observed. After the treatment all indicators of the total blood analysis were within the physiological rate. Conducted antibiotic therapy contributed to the increase of phagocytic index and a considerable increase of serum lysozyme activity. After Danoflox 2.5% administration a rising of serum albumin and β-globulin percentage and normalization of the level of α- and γ-globulins in the proteinogram was observed. Other investigated serum biochemical parameters of animals were not over the acceptable physiological limits.

Keywords: fluoroquinolones, danofloxacin, pigs, piglets, colibacteriosis, Еscherichia coli, therapeutic efficiency, safeness

  1. Alexander TJL. Neonatal diarrhoea in pigs. In: Gyles CL. (ed.) Escherichia coli in domestic animals and humans. Wallingford: CAB International, 1994: 151–170. ISBN 0851989217. Available at: https://www.cabi.org/ISC/abstract/19952213028
  2. Aliabadi FS, Lees P. Pharmacokinetic-pharmacodynamic integration of danofloxacin in the calf. Res. Vet. Sci. 2003; 74 (3): 247–259. https://doi.org/10.1016/S0034-5288(03)00005-5
  3. Bywater R, Deluyker H, Deroover E, de Jong A, Marion H, McConville M, Rowan T, Shryock T, Shuster D, Thomas V, Vallé M, Walters J. European survey of antimicrobial susceptibility among zoonotic and commensal bacteria isolated from food-producing animals. J. Antimicrob. Chemother. 2004; 54 (4): 744–754. https://doi.org/10.1093/jac/dkh422
  4. Chorna IV, Vysotsky IY. Clinical enzymology. Enzymodiagnostics. Sumy, Sumy State University, 2013: 244 p. Available at: https://essuir.sumdu.edu.ua/handle/123456789/30436 (in Ukrainian)
  5. Danofloxacin product information (A180, Pfizer-Canada). In: Arrioja-Dechert A (ed.). Compendium of veterinary products. CD ed. Port Huron, MI: North American Compendiums, Inc. 2005.
  6. Determination of bacteriostatic and bactericidal concentration of antibacterial preparations by the method of serial dilutions: methodical instructions. Kyiv, 2007: 7 p. (in Ukrainian)
  7. Determination of the microorganism sensitivity to antimicrobials by the method of diffusion into agar using standard disks with antibiotics: methodical instructions. Lviv, 2010: 12 p. (in Ukrainian)
  8. Fairbrother JM, Gyles CL. Colibacillosis. In: Zimmerman JJ, Karriker LA, Ramirez A, Schwartz KJ, Stevenson GW (eds). Disease of Swine. 10th ed. 2012: 723–747.
  9. Golovko AN, Ushkalov VA, Skrypnik VG. Microbiological and virological studies in veterinary medicine: a reference manual. Kharkiv: NTMG, 2007: 512 p. (in Ukrainian)
  10. Gordon DM, Cowling A. The distribution and genetic structure of Escherichia coli in Australian vertebrates: host and geographic effects. Microbiology. 2003; 149 (12): 3575–3586. https://doi.org/10.1099/mic.0.26486-0
  11. Hooper DC, Wolfson JS. Mechanism of quinolone action and bacterial killing. In: Quinolone Antimicrobial Agents. 2nd ed. Washington, Eds. Amer. Soc. For Microbiol., 1993: 482–512.
  12. Kidsley AK, Abraham S, Bell JM, O’Dea M, Laird TJ, Jordan D, Mitchell P, McDevitt CA, Trott DJ. Antimicrobial susceptibility of Escherichia coli and Salmonella spp. isolates from healthy pigs in Australia: results of a pilot national survey. Front. Microbiol. 2018; 9: 1207. https://doi.org/10.3389/fmicb.2018.01207
  13. Kotsyumbas IY, Kotsyumbas GI, Golubiy E.M. Comprehensive assessment of the effect of veterinary drugs on the morphofunctional state of the immune system: methodical recommendations. Lviv, 2009: 63 p. (in Ukrainian)
  14. Kravtsiv RY, Zakhariv OY, Semenyuk VI, Turko IB. Veterinary Microbiology: Handbook for higher education. Lviv, S. Z. Gzhytskyi LNUVM&B, 2008: 418 p. (in Ukrainian)
  15. Levchenko VI, Sokolyuk VM, Bezuh VM. Animal blood research and clinical interpretation of the results obtained: methodical recommendations for the students of the Faculty of Veterinary Medicine managers and students of the Institute of Postgraduate Training of Veterinary Medicine Managers and Specialists. Bila Tserkva, 2002: 56 p. (in Ukrainian)
  16. Lytvyn VP, Oliinyk LV, Kornienko LE, Yarchuk BM, Dombrowski OB, Kornienko LM. Factor Diseases of Farm Animals. Bila Tserkva, 2002, 303 p. (in Ukrainian)
  17. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clinical Microbiology Reviews, 1998; 11 (1): 142–201. https://doi.org/10.1128/CMR.11.1.142
  18. Ozawa M, Baba K, Shimizu Y. Asai T. Comparison of in vitro activities and pharmacokinetics/pharmacodynamics estimations of veterinary fluoroquinolones against avian pathogenic Escherichia coli isolates. Microb. Drug Resist. 2010; 16 (4): 327–332. https://doi.org/10.1089/mdr.2010.0024
  19. Papich MG, Riviere JE. Fluoroquinolone antimicrobial drugs. In: Adams HR (ed.). Veterinary Pharmacology and Therapeutics. 8th ed. Ames, Iowa State University Press. 2001: 898–912.
  20. Raemdonck DL, Tanner AC, Tolling ST, Michener SL. In vitro susceptibility of avian Escherichia coli and Pasteurella multocida to danofloxacin and five other antimicrobials. Avian Dis. 1992; 36 (4): 964–967. https://doi.org/10.2307/1591556
  21. Shryock TR, Apley M, Berson M, Gray JT, Jones RN, Papich MG, Shuster DE, Thornsberry C, Walker RD, Wu CC. NCCLS. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; informational supplement. NCCLS document M31–S1, 2004; 24 (17): 38 p. ISBN 1-56238-534-8.
  22. Sjölund M., Zoric M., Wallgren P. Financial impact on pig production: III. Gastrointestinal disorders: Proceedings of the 6th European Symposium of Porcine Health Management. Sorrento, Italy, 2014: 189.
  23. Smith LT, Lewin CS. Chemistry and mechanisms of action of the quinolone antibacterials. In: Andriole V (ed.). Quinolones. Academ. Press. 1988: 23–42. https://doi.org/10.1016/B978-0-12-059515-0.50006-8
  24. Souto MS, Coura FM, Dorneles EM, Stynen APR, Alves TM, Santana JA, Pauletti RB, Guedes RMC, Viott AM, Heinemann MB, Lage AP. Antimicrobial susceptibility and phylotyping profile of pathogenic Escherichia coli and Salmonella enterica isolates from calves and pigs in Minas Gerais, Brazil. Trop. Anim. Health Prod. 2017; 49 (1): 13–23. https://doi.org/10.1007/s11250-016-1152-0
  25. Statistical principles for veterinary clinical trials. CVMP/EWP/81976/2010; Demonstration of efficacy for veterinary medicinal products containing antimicrobial substances. CVMP/627/2001.
  26. Stetsko TI, Muzyka VP, Gunchak VM. Critically important antimicrobials for veterinary medicine. Scientific Bulletin of LNUVM&B. 2018; 20 (87):19–26. https://doi.org/10.15421/nvlvet8704 (in Ukrainian)
  27. Sunderland SJ, Sarasola P, Rowan TG, Giles CJ, Smith DG. Efficacy of danofloxacin 18% injectable solution in the treatment of Escherichia coli diarrhoea in young calves in Europe. Res. Vet. Sci., 2003; 74 (2): 171–178. https://doi.org/10.1016/S0034-5288(02)00186-8
  28. Turnidge J, Bordash G. Statistical methods for establishing quality control ranges for antibacterial agents in clinical and laboratory standards institute susceptibility testing. Antimicrob. Agents Chemother. 2007; 51: 2483–2488. https://doi.org/10.1128/AAC.01457-06
  29. Vlizlo VV, Fedoruk RS, Ratych IB. Laboratory methods of research in biology, animal husbandry and veterinary medicine: a handbook. Lviv: Spolom, 2012: 764 p. (in Ukrainian)
  30. Winnicka A. Wartosci referencyjne podstawowych badan laboratoryjnych w weterynarii. Warszawa, 1997: 115 s. (in Polish)
  31. Yang Y, Zhang Y, Li J, Cheng P, Xiao T, Muhammad I, Yu H, Liu R, Zhang X. Susceptibility breakpoint for Danofloxacin against swine Escherichia coli. BMC Veterinary Research. 2019; 15: 51. https://doi.org/10.1186/s12917-019-1783-2

gslogoICLOGO

cr

nbuv

ouci0

WorldCat Logo

oa

Search